Candel offers an asymmetric late-stage biotech setup: validated prostate cancer Phase III data, strong cash runway, non-dilutive launch funding potential, and major binary regulatory risk.
Overview
Candel Therapeutics is a pre-revenue clinical-stage oncology biotech developing off-the-shelf viral immunotherapies that reprogram tumors into immune-activating sites. Lead asset CAN-2409 has generated strong Phase III prostate cancer data and survival-tail signals in NSCLC, while CAN-3110 targets recurrent high-grade glioma. The company has no commercial sales today but is funded through equity, partnerships, and royalty monetization. If approved, its therapies could serve urologists, oncologists, hospitals, and payers seeking durable cancer control with localized safety advantages.